Antoine Andremont is currently Emeritus Professor at the Paris Diderot University Medical School, France, a scientific advisor at the French Ministry of Higher Education, Research and Innovation, and serves as an expert witness for the French National Highest Judiciary Court (Cour de Cassation).
He is also the co-founder and a senior scientific advisor at biotechnology company Da Volterra – which he created in 2000 to research and understand the impact of antibiotics on the intestinal flora microbiota, the development and dissemination of bacterial resistance and the means to prevent it.
Most of his career has been devoted to research in this field. Antoine has worked as the Professor of Microbiology at both the University Paris Diderot Medical School, and the University Paris-South School of Pharmacy; has been Head of the Bacteriology laboratory at Bichat Hospital in Paris and Vice-head of the Bacteriology Laboratory, Institut Gustave-Roussy, Villejuif in France.
His work has resulted in over 250 publications and more than 10 patents that constituted the basis for the funding of Da Volterra, which has currently more than 30 employees in Paris and a product (DAV132) entering phase II studies.
Antoine has served on the scientific boards of many national and international organisations and institutions, both private and public, and has a great deal of experience in international research including in low-and-middle-income countries (LMICs).
He has also been instrumental in the development of the WHO ESBL-E. coli surveillance programme (the so-called tricycle programme), which is currently in its early implementation phase in 10 countries.